Revance Therapeutics 주식 (NASDAQ: RVNC)

에 대한 최신 뉴스 Revance Therapeutics (NASDAQ:RVNC) 주식

Revance Therapeutics

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics, Inc. - Common Stock

Revance Therapeutics Inc

WIIM

RVNC

Revance Therapeutics shares are trading higher after the company announced Teoxane SA submitted a proposal to acquire the company for $3.60 per share in cash.

Teoxane SA Submits Proposal To Acquire Revance For $3.60 Per Share In Cash; Proposal Represents Premium Over $3.10 Agreement With Crown Laboratories

Barclays analyst Balaji Prasad maintains Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Equal-Weight and lowers the price target from $7 to $3.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3

Board of Directors of Revance Recommend Stockholders Tender their Shares
JOHNSON CITY, Tenn., Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance Therapeutics, Inc., ("Revance") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) at a price of $3.10 per share in cash. The tender offer is being made in connection with the Amended and Restated Merger Agreement, dated December 7, 2024 (as amended or supplemented from time to time, the "A&amp;R Merger Agreement").

Crown Laboratories Announces That It Has Commenced A Cash Tender Offer To Acquire All Outstanding Shares Of Common Stock Of Revance Therapeutics At A Price Of $3.10 Per Share In Cash

Mizuho analyst Vamil Divan maintains Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Neutral and lowers the price target from $6.66 to $3.1.

Mizuho Maintains Neutral on Revance Therapeutics, Lowers Price Target to $3.1

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock rose 110.0% to $4.41 during Monday's pre-market session. The company's market cap stands at $3.6 million. </li>
<li>Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) stock rose 34.05% to $2.48. The market value of their outstanding shares is at $92.8 million. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares increased by 25.17% to $1.84. The company's market cap stands at $148.9 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares increased by 20.82% to $14.39. The company's market cap stands at $118.7 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares moved upwards by 16.71% to $3.77. The market value of their outstanding shares is at $15.9 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares increased by 14.22% to $8.94. The company's market cap stands at $470.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) stock decreased by 72.1% to $5.6 during Monday's pre-market session. The company's market cap stands at $200.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 51.33% to $1.65. The company's market cap stands at $2.6 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares fell 40.22% to $11.3. The company's market cap stands at $24.5 billion. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares decreased by 20.69% to $3.03. The company's market cap stands at $317.8 million. </li>
<li>Invizyne Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZTC#NASDAQ">IZTC</a>) shares fell 18.36% to $10.81. The market value of their outstanding shares is at $103.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 16.46% to $1.98. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BIOA

CRVO

IPHA

IZTC

RADX

SONN

STRM

12 Health Care Stocks Moving In Monday's Pre-Market Session

Revance shares are trading lower after the company announced an amended and restated merger agreement with Crown Laboratories, under which Crown will commence a tender offer to acquire all outstanding shares of Revance's common stock for $3.10 per share in cash.

Crown Laboratories And Revance Enter Amended And Restated Merger Agreement; Under Terms Of Amended And Restated Agreement, Crown Will Commence Tender Offer To Acquire All Outstanding Shares Of Revance's Common Stock For $3.10 Per Share In Cash

Revance Therapeutics Extends Tender Offer Deadline With Crown Laboratories And Reba Merger Sub To December 9 Amid Ongoing Discussions, With Potential For Further Delays Or Modifications To Merger Agreement Terms, Including Offer Price Adjustments

Revance Therapeutics Extends Tender Offer Deadline For Merger With Crown Laboratories To December 3, 2024 Amid Ongoing Discussions

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.
Shares of Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) rose sharply during Monday's session following <a href="https://www.benzinga.com/news/earnings/24/11/41900813/tyson-foods-q4-earnings-revenue-and-eps-beat-beef-gains-outshine-chicken-dip-more">upbeat quarterly earnings</a>.
The company reported fourth-quarter adjusted earnings per share of 92 cents beating the street view 69 cents. Quarterly revenues of $13.565 billion (+1.6%) outpaced the analyst consensus of $13.392 billion.
Tyson shares jumped 8.5% to close at $63.79 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares surged 39.8% to $2.2781. Needham reiterated a Buy rating on the stock and Cantor Fitzgerald reiterated an Overweight rating.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) gained 33.6% to $1.5827.</li>
<li>Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) rose 30.2% to $9.57 after the company reported better-than-expected third-quarter financial results. Also, UBS initiated coverage on the stock with a Buy rating and announced a price target of $26.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) gained 25.5% to $112.97 following strong quarterly sales.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) rose 19% to $4.1300.</li>
<li>Priority Technology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) gained 16.7% to $8.63.</li>
<li>Alight, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALIT#NYSE">ALIT</a>) shares rose 13.6% to $8.48 after the company reported better-than-expected third-quarter sales results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates..</li>
<li>Grab Holdings Limite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) gained 11.7% to $4.8990 after the company reported better-than-expected quarterly financial results and raised its FY25 revenue guidance above estimates.</li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) gained 10.8% to $108.00 after the company reported better-than-expected third-quarter sales, despite a miss on EPS estimates..</li>
<li>The Buckle, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) rose 5.4% to $47.57 after UBS upgraded the stock from Sell to Neutral and raised its price target from $31 to $46.</li>
<li>Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) gained 4.4% to $129.21 following third-quarter results. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41877638/jim-cramer-tech-stock-go-to-160-recommends-buying-dominos-pizza">Jim Cramer: This Tech Stock Can &#8216;Go To 160,&#8217; Recommends Buying Domino&#8217;s Pizza</a></li>
</ul>

Markets

Trading Ideas

ALIT

GRAB

NWTN

PRTH

SHOP

TSHA

Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares increased by 75.3% to $0.46 during Friday's pre-market session. The company's market cap stands at $2.8 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) stock rose 29.94% to $56.42. The company's market cap stands at $10.4 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock rose 26.31% to $22.8. The market value of their outstanding shares is at $2.0 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) shares moved upwards by 20.39% to $3.01. The company's market cap stands at $237.4 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock rose 15.11% to $1.37. The company's market cap stands at $13.9 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares rose 14.99% to $1.15. The company's market cap stands at $89.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock declined by 51.8% to $0.69 during Friday's pre-market session. The company's market cap stands at $13.1 million. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) stock decreased by 40.06% to $4.7. The market value of their outstanding shares is at $665.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock decreased by 38.75% to $15.05. The market value of their outstanding shares is at $1.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock fell 33.34% to $1.86. The market value of their outstanding shares is at $765.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares declined by 29.7% to $0.69. The market value of their outstanding shares is at $79.6 million. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares decreased by 25.61% to $4.3. The company's market cap stands at $447.9 million. The company's, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALVR

CTMX

DOCS

FTRE

INDP

MRVI

PRPH

TIVC

TNYA

12 Health Care Stocks Moving In Friday's Pre-Market Session

Needham analyst Serge Belanger reiterates Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Revance Therapeutics

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Neutral and maintains $6.6 price target.

HC Wainwright & Co. Reiterates Neutral on Revance Therapeutics, Maintains $6.6 Price Target

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock rose 39.8% to $0.36 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock increased by 33.57% to $24.11. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q3 earnings came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) stock moved upwards by 32.05% to $20.39. The market value of their outstanding shares is at $358.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares increased by 21.59% to $3.2. The company's market cap stands at $83.1 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock rose 19.31% to $0.45. The market value of their outstanding shares is at $6.0 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock increased by 18.7% to $3.3. The company's market cap stands at $217.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 48.1% to $0.74 during Friday's regular session. The market value of their outstanding shares is at $14.1 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock fell 41.11% to $14.47. The company's market cap stands at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares fell 37.31% to $4.92. The market value of their outstanding shares is at $695.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock fell 36.6% to $3.67. The company's market cap stands at $381.8 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock declined by 32.08% to $1.9. The market value of their outstanding shares is at $779.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) stock decreased by 29.23% to $0.69. The market value of their outstanding shares is at $80.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNOX

NOTV

RIGL

12 Health Care Stocks Moving In Friday's Intraday Session

Revance Therapeutics shares are trading lower after the company reported better-than-expected Q3 EPS results.

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares rose 127.3% to $0.59 during Friday's pre-market session. The market value of their outstanding shares is at $3.6 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) stock moved upwards by 39.82% to $60.71. The market value of their outstanding shares is at $11.2 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 14.42% to $1.19. The market value of their outstanding shares is at $52.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 13.97% to $0.55. The market value of their outstanding shares is at $47.4 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares rose 13.68% to $20.52. The market value of their outstanding shares is at $1.8 billion. The company's, Q3 earnings came out today. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares moved upwards by 12.99% to $1.13. The market value of their outstanding shares is at $88.2 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares declined by 51.0% to $0.7 during Friday's pre-market session. The market value of their outstanding shares is at $13.3 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock decreased by 35.5% to $15.85. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares fell 31.9% to $1.9. The company's market cap stands at $781.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares declined by 28.19% to $5.63. The market value of their outstanding shares is at $796.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares fell 15.23% to $4.9. The market value of their outstanding shares is at $510.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares fell 14.42% to $0.84. The company's market cap stands at $96.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EYEN

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock moved upwards by 127.3% to $0.59 during Friday's pre-market session. The market value of their outstanding shares is at $3.6 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares moved upwards by 39.82% to $60.71. The company's market cap stands at $11.2 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 14.42% to $1.19. The market value of their outstanding shares is at $52.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 13.97% to $0.55. The market value of their outstanding shares is at $47.4 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares increased by 13.68% to $20.52. The company's market cap stands at $1.8 billion. The company's, Q3 earnings came out today. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares increased by 12.99% to $1.13. The market value of their outstanding shares is at $88.2 million. As per the press release, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares fell 51.0% to $0.7 during Friday's pre-market session. The market value of their outstanding shares is at $13.3 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock fell 35.5% to $15.85. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock declined by 31.9% to $1.9. The market value of their outstanding shares is at $781.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares fell 28.19% to $5.63. The company's market cap stands at $796.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock declined by 15.23% to $4.9. The market value of their outstanding shares is at $510.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares decreased by 14.42% to $0.84. The market value of their outstanding shares is at $96.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.38) by 2.63 percent. This is a 77.3 percent increase over losses of $(1.63) per share from the same period last year. The company reported quarterly sales of $59.88 million which missed the analyst consensus estimate of $68.20 million by 12.20 percent. This is a 10.66 percent increase over sales of $54.11 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Revance Therapeutics Q3 EPS $(0.37) Beats $(0.38) Estimate, Sales $59.88M Miss $68.20M Estimate

Revance Therapeutics ticks higher as holder says Crown deal undervalues company

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revance Therapeutics (RVNC – Research Report) and ...

Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (RVNC) and Neurocrine (NBIX)

Barclays lowered the firm's price target on Revance (RVNC) to $3 from $7 and keeps an Equal Weight rating on the shares. Published first on TheFly ...

Revance price target lowered to $3 from $7 at Barclays

Teoxane SA announced that on January 6, it submitted a proposal to the Board of Directors of Revance (RVNC) Therapeutics to acquire Revance for $3....

Teoxane announces proposal to acquire Revance for $3.60 per share in cash

Revance Therapeutics jumps after Teoxane offers $3.60 a share

THE LAWSUIT: A class action securities lawsuit was filed against Revance Therapeutics, Inc. (RVNC) that seeks to recover losses of Revance sharehol...

Class Action Filed Against Revance Therapeutics, Inc. (RVNC) – March 04, 2025 Deadline to Join – Contact Levi & Korsinsky LLP

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Disney (DIS) plans to combine its Hulu...

Disney to own 70% of Fubo, Trudeau to resign as party leader: Morning Buzz

Needham analyst Serge Belanger has maintained their neutral stance on RVNC stock, giving a Hold rating on December 23. Serge Belanger has given his...

Hold Rating Issued Amid Acquisition Uncertainty for Revance Therapeutics

Mizuho Securities analyst Uy Ear has maintained their neutral stance on RVNC stock, giving a Hold rating yesterday. Uy Ear has given his Hold ratin...

Hold Rating on Revance Therapeutics Amid Acquisition Bid Uncertainty

Revance gains as it plans to enter talks with Teoxane on likely superior bid

ARBE

FUBO

FWRD

GOOG

GOOGL

HCWC

LWAY

NBIX

NVDA

PAYX

PLTR

PPTA

PYCR

PYPL

SEDG

SSNLF

TMUS

TSLA

TTAN

UBER

Legal

Press Releases

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. (RVNC)

Penny Stocks

Small Cap

Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action

RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Stockholder Notice: Robbins LLP Informs Stockholders of the Revance Therapeutics, Inc. Class Action Lawsuit

RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

REVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. and Encourages Investors to Contact the Firm

Deadline Approaching: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Class Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join – Contact Levi & Korsinsky

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC

Comments

Revance Therapeutics

뉴스

에 대한 최신 뉴스 Revance Therapeutics (NASDAQ:RVNC) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌